Nucleophosmin Mutant Peptide-HLA Complex

The Nucleophosmin mutant peptide-HLA complex refers to a molecular structure formed when peptides derived from mutated nucleophosmin 1 (NPM1) protein are presented on the cell surface by human leukocyte antigen (HLA) class I molecules. This complex is of particular interest in acute myeloid leukemia (AML), where NPM1 mutations are common and generate unique neoantigenic peptides that can be recognized by cytotoxic T cells. The mutant NPM1 protein results from recurrent frameshift insertions at the gene's C-terminal end in about 30–35% of AML cases. These mutations create an alternative reading frame encoding an immunogenic neoepitope that is processed intracellularly and loaded onto HLA class I molecules for presentation on the cell surface. The resulting peptide-HLA complexes can be specifically recognized by CD8+ T cells as foreign targets, making them attractive targets for immunotherapy.

TCR-mediated T cell activation and cytotoxic killing of cells presenting the complex